Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:FUSNNASDAQ:HALONASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$19.77+1.3%$20.67$9.35▼$25.67$4.72B0.573.14 million shs2.36 million shsFUSNFusion Pharmaceuticals$21.55$21.50$2.31▼$21.60$1.83B-0.691.69 million shsN/AHALOHalozyme Therapeutics$54.73+0.6%$59.27$42.01▼$70.51$6.74B1.261.63 million shs1.83 million shsRGENRepligen$122.32+0.9%$129.03$102.97▼$182.52$6.87B1.21740,892 shs1.07 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-1.91%-3.03%-20.40%+26.36%+105.15%FUSNFusion Pharmaceuticals0.00%0.00%0.00%0.00%+0.47%HALOHalozyme Therapeutics+0.02%+0.93%-10.14%-5.67%+26.35%RGENRepligen-1.11%+0.81%-15.63%-22.59%-22.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.8927 of 5 stars2.62.00.00.04.02.51.9FUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHALOHalozyme Therapeutics4.8158 of 5 stars3.11.00.04.43.42.54.4RGENRepligen4.9003 of 5 stars4.32.00.04.54.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2522.66% UpsideFUSNFusion Pharmaceuticals 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.17Hold$61.9013.10% UpsideRGENRepligen 2.64Moderate Buy$173.2541.64% UpsideCurrent Analyst Ratings BreakdownLatest FUSN, HALO, RGEN, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/5/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.004/30/2025RGENRepligenRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.004/29/2025RGENRepligenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $190.004/29/2025RGENRepligenWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$160.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.27$0.06 per share311.70$0.60 per share32.95FUSNFusion Pharmaceuticals$2.07M885.53N/AN/A$3.07 per share7.02HALOHalozyme Therapeutics$1.08B6.22$4.43 per share12.35$2.95 per share18.55RGENRepligen$650.43M10.57$2.28 per share53.61$35.19 per share3.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8570.6128.65N/A17.80%53.20%26.07%8/14/2025 (Estimated)FUSNFusion Pharmaceuticals-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/AHALOHalozyme Therapeutics$281.59M$3.7615.968.800.4243.74%157.78%25.34%8/5/2025 (Estimated)RGENRepligen$35.60M-$0.45N/A51.834.54-4.64%4.21%2.94%7/29/2025 (Estimated)Latest FUSN, HALO, RGEN, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26FUSNFusion Pharmaceuticals0.2110.6410.64HALOHalozyme Therapeutics4.147.809.15RGENRepligen0.2610.448.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%FUSNFusion Pharmaceuticals72.85%HALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%FUSNFusion Pharmaceuticals7.75%HALOHalozyme Therapeutics2.90%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableFUSNFusion Pharmaceuticals10185.06 million78.47 millionOptionableHALOHalozyme Therapeutics390123.22 million120.20 millionOptionableRGENRepligen2,02056.18 million55.36 millionOptionableFUSN, HALO, RGEN, and ADMA HeadlinesRecent News About These CompaniesWhy Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?May 29 at 12:36 PM | zacks.comRepligen Co. (NASDAQ:RGEN) Position Raised by Polar Asset Management Partners Inc.May 29 at 5:14 AM | marketbeat.comTidal Investments LLC Decreases Position in Repligen Co. (NASDAQ:RGEN)May 29 at 3:57 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $33.88 Million Stock Position in Repligen Co. (NASDAQ:RGEN)May 28 at 4:48 AM | marketbeat.comRepligen Announces Publication of the Company’s 2024 Corporate Sustainability ReportMay 27 at 10:20 AM | finance.yahoo.comRepligen Announces Publication of the Company's 2024 Corporate Sustainability ReportMay 27 at 8:00 AM | investing.comRepligen Announces Publication of the Company's 2024 Corporate Sustainability ReportMay 27 at 7:30 AM | globenewswire.comRepligen Co. (NASDAQ:RGEN) Shares Bought by Two Sigma Advisers LPMay 24, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by AWM Investment Company Inc.May 23, 2025 | marketbeat.comTeza Capital Management LLC Sells 10,705 Shares of Repligen Co. (NASDAQ:RGEN)May 23, 2025 | marketbeat.comRepligen Corporation to Present at William Blair Growth ConferenceMay 22, 2025 | uk.finance.yahoo.comTwo Sigma Investments LP Lowers Stake in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comPoint72 Asia Singapore Pte. Ltd. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Stock Position in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys 3,000 Shares of Repligen Co. (NASDAQ:RGEN)May 20, 2025 | marketbeat.comGotham Asset Management LLC Has $965,000 Stake in Repligen Co. (NASDAQ:RGEN)May 20, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives $173.25 Average Price Target from AnalystsMay 20, 2025 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by AnalystsMay 19, 2025 | marketbeat.comBank of America Corp DE Trims Holdings in Repligen Co. (NASDAQ:RGEN)May 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $132.23 Million Stake in Repligen Co. (NASDAQ:RGEN)May 17, 2025 | marketbeat.comInsider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN)May 17, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumMeta's Institutional & Insider Data Fuels Bulls Despite DisparityBy Leo Miller | May 28, 2025View Meta's Institutional & Insider Data Fuels Bulls Despite DisparityFUSN, HALO, RGEN, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$19.77 +0.26 (+1.33%) Closing price 04:00 PM EasternExtended Trading$19.81 +0.04 (+0.20%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Fusion Pharmaceuticals NASDAQ:FUSNFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Halozyme Therapeutics NASDAQ:HALO$54.73 +0.30 (+0.55%) Closing price 04:00 PM EasternExtended Trading$54.08 -0.65 (-1.19%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$122.32 +1.14 (+0.94%) Closing price 04:00 PM EasternExtended Trading$122.32 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
